← All indications
Digestive System Neoplasms
Tumors or cancer of the DIGESTIVE SYSTEM.
Subtype terms (5)
More specific conditions that are subtypes of Digestive System Neoplasms in the MeSH hierarchy.
- Biliary Tract Neoplasms
214 drugs (80 approved, 134 experimental)
- Gastrointestinal Neoplasms
172 drugs (91 approved, 81 experimental)
- Liver Neoplasms
456 drugs (185 approved, 271 experimental)
- Pancreatic Neoplasms
1361 drugs (372 approved, 989 experimental)
- Peritoneal Neoplasms
102 drugs (53 approved, 49 experimental)
Drugs by status
Phase 4 trials (1)
Phase 3 trials (13)
Phase 2 trials (40)
- decitabine
- afatinib
- anlotinib
- allogeneic natural killer cells
- donafenib
- flucytosine
- nivolumab
- pembrolizumab
- regorafenib
- palbociclib
- panitumumab
- carboplatin
- alectinib
- tumor necrosis factor
- autologous cytokine induced killer cells
- autologous fecal microbiota
- oligo fucoidan
- gimeracil
- oteracil
- oxaliplatin
- cisplatin
- tegafur
- autologous dendritic cells loaded with autologous tumor lysate
- etoposide
- folfirinox
- oncoxin-viusid
- kn046
- camrelizumab
- sintilimab
- toripalimab
- +10 more
Phase 1 trials (21)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (54)
- Daiichi Sankyo
- Bristol-Myers Squibb
- Eli Lilly
- Exelixis
- Aventis
- Sanofi
- Ipsen
- Bayer
- Catalysis SL
- FeRx
- Hengrui Therapeutics, Inc.
- Imugene Limited
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Shenzhen Hornetcorn Bio-technology Company, LTD
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Boehringer Ingelheim
- Transgene
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- University of Pittsburgh
- Harvard University
- Emory University
- German Cancer Research Center
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)
- Guangzhou Medical University
- Hellenic Cooperative Oncology Group
- Johns Hopkins University
- Qingdao University
- University of Heidelberg
- University of Maryland
- +24 more
Organization Involved with Phase 1 Indications (33)
- Poniard Pharmaceuticals
- Millennium Pharmaceuticals
- Merck
- Pharmacyclics
- Genentech
- BioMed Valley Discoveries, Inc
- Blueprint Medicines Corporation
- Curegenix Inc.
- Handok Pharmaceuticals Co., Ltd.
- Jeil Pharmaceutical Co., Ltd.
- Leadiant Biosciences, Inc.
- Minneamrita Therapeutics LLC
- Inspirna, Inc.
- Syndax Pharmaceuticals
- Otsuka
- Fondazione Giovanni Pascale
- Cornell University
- Nanjing Medical University
- University of Groningen
- University of Nottingham
- Yale University
- University of Utah
- CJ HealthCare Corp.
- Free University of Amsterdam
- Xencor
- Medpace, Inc.
- University of Texas at Houston
- Hallym University
- University of Illinois at Chicago
- ICON
- +3 more
Organization Involved with Other Experimental Indications (4)